Intuitive Surgical, Inc.

(NASDAQ Global Select)
Back to all articles
Bullish +65

UBS keeps USD 500.00 target for Intuitive Surgical stock

Analyst upgrade AI-generated analysis

πŸ“ˆ UBS maintained a Buy rating and a USD 500 price target for Intuitive Surgical on October 13, 2026.

πŸ’° Second-quarter revenue reached USD 2.89 billion, up 18.40% year over year through June 30, 2026.

πŸ“Š Operating margin stood at 34% with operating cash flow of USD 1.06 billion in the second quarter.

πŸ” UBS analyst report cited procedure-volume concerns as potentially overly cautious for Intuitive Surgical.

⚠️ A possible 4% headwind from the Extended Use Program is expected to impact Intuitive Surgical in 2027.

πŸ“… Third-quarter results are scheduled for release on October 20, 2026, with consensus revenue at USD 2.91 billion.

🎯 Analysts anticipate earnings per share of USD 2.65 for the upcoming third quarter.

πŸ€– Intuitive Surgical develops robotic-assisted systems led by the da Vinci platform for minimally invasive surgery.

πŸ“° Company released a meta-analysis covering 13 benign conditions in September 2026 to expand clinical applications.

πŸ’Ή Stock traded at EUR 377.00 on October 15, 2026, up 0.17% from the previous Xetra close.

Bullish Signals
  • UBS maintained a Buy rating and a USD 500 price target for Intuitive Surgical, citing that procedure-volume concerns appeared overly cautious.
  • Second-quarter revenue reached USD 2.89 billion, representing an 18.40% year-over-year increase driven by strong demand.
  • The company achieved a 34% operating margin and generated USD 1.06 billion in operating cash flow during the second quarter.
  • Intuitive Surgical recently highlighted a meta-analysis covering 13 benign conditions, expanding its clinical reach for the da Vinci platform.
Risk Factors
  • UBS analyst report identified a possible 4% headwind from the Extended Use Program expected to impact Intuitive Surgical in 2027.
  • Investors are monitoring whether third-quarter revenue of USD 2.91 billion can sustain the 18.40% growth rate seen in the prior quarter.
Full Analysis
Intuitive Surgical (ISRG) is maintaining a strong financial trajectory ahead of its third-quarter earnings report scheduled for October 20, 2026. The company recently reported robust second-quarter results with revenue reaching USD 2.89 billion, representing an 18.40% year-over-year increase. Operating margins remained healthy at 34%, while operating cash flow hit USD 1.06 billion for the period ended June 30, 2026. Analyst sentiment remains positive as UBS maintained its Buy rating and a USD 500 price target on October 13, 2026. The analyst noted that concerns regarding procedure volume appeared overly cautious in their view. However, the report highlighted a potential 4% headwind expected from the Extended Use Program in 2027, providing investors with a specific counter-factor to consider before the upcoming results. Market consensus estimates for the third quarter project revenue of USD 2.91 billion and earnings per share of USD 2.65. The stock is currently trading at EUR 377.00, slightly above its recent Xetra close. Investors will be watching to see if the projected revenue can extend the impressive growth rate seen in the second quarter. Intuitive Surgical continues to lead the market with its da Vinci robotic-assisted systems for minimally invasive surgery. The company recently highlighted a meta-analysis covering 13 benign conditions, further expanding its clinical footprint. With the upcoming earnings call on October 20, the market will test whether Intuitive can sustain its momentum amidst potential procedural volume headwinds.